Hepatotoxicity Risk Assessment

Hepatotoxicity risk assessment evaluates pharmaceutical potential causing liver injury through standardised preclinical and clinical approaches. Hepatocyte toxicity testing employs cultured liver cells detecting cytotoxicity. HepG2 cells provide standardised human hepatic model. Immunological liver injury prediction employs hapten-protein interaction models. Mechanism-of-action analysis predicts hepatotoxic potential.

Clinical monitoring through liver enzyme measurement detects early hepatotoxicity. Dose-dependent hepatotoxicity indicates dose-limiting toxicity. Idiosyncratic reactions suggest immunological mechanisms. Regulatory warnings highlight hepatotoxic risks. Post-approval surveillance detects rare hepatotoxicity patterns.